Muneer J Al-Husseini1, Anas M Saad2, Khalid A Jazieh3, Abdelmagid M Elmatboly4, Ahmad Rachid1, Mohamed M Gad5, Inas A Ruhban6, Talal Hilal7. 1. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lofty Elsayed Street, Cairo, 11566, Egypt. 2. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lofty Elsayed Street, Cairo, 11566, Egypt. Anassaad256@gmail.com. 3. Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA. 4. Faculty of Medicine, Al-Azhar University, Cairo, Egypt. 5. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA. 6. Pathology Department, Faculty of Medicine, Damascus University, Cairo, Egypt. 7. Division of Hematology/Oncology, Mayo Clinic Cancer Center, 5881 E. Mayo Blvd, Phoenix, AZ, 85054, USA. hilal.talal@mayo.edu.
Abstract
PURPOSE: Previous studies of ethnic disparities in colorectal cancer (CRC) have focused mainly on patients of Caucasian and African-American descent. We aimed to evaluate outcomes for a range of races, representing a broader demographic of the US population. METHODS: The Surveillance, Epidemiology, and End Results database was queried to identify patients with CRC diagnosed between 1994 and 2014. We performed unadjusted Kaplan-Meier test and multivariable covariate-adjusted Cox models to calculate the overall and CRC-specific survival of patients according to their race. RESULTS: We identified 401,723 patients diagnosed with CRC between 1994 and 2014. Overall survival (OS) and CRC-specific survival were compared across different races stratified by age, sex, marital status, disease stage and grade, and undergoing surgery as a treatment. Overall, Asian/Pacific Islanders and Hispanics had improved CRC-specific survival compared to Whites (HR = 0.873, 95%CI 0.853-0.893, P < .001, and HR = 0.958, 95%CI 0.937-0.979, P < .001, respectively). Blacks had the worst CRC-specific survival outcomes when compared to Whites (HR = 1.215, 95%CI 1.192-1.238, P < .001). Racial disparity persisted when looking at two different time periods (1994-2003 and 2004-2014). CONCLUSIONS: Asians/Pacific Islanders have improved outcomes from CRC compared to other races. Multifactorial, including genetic, environmental, and socioeconomic factors appear to influence outcomes and need to be addressed separately in order to reduce racial disparities among patients with CRC.
PURPOSE: Previous studies of ethnic disparities in colorectal cancer (CRC) have focused mainly on patients of Caucasian and African-American descent. We aimed to evaluate outcomes for a range of races, representing a broader demographic of the US population. METHODS: The Surveillance, Epidemiology, and End Results database was queried to identify patients with CRC diagnosed between 1994 and 2014. We performed unadjusted Kaplan-Meier test and multivariable covariate-adjusted Cox models to calculate the overall and CRC-specific survival of patients according to their race. RESULTS: We identified 401,723 patients diagnosed with CRC between 1994 and 2014. Overall survival (OS) and CRC-specific survival were compared across different races stratified by age, sex, marital status, disease stage and grade, and undergoing surgery as a treatment. Overall, Asian/Pacific Islanders and Hispanics had improved CRC-specific survival compared to Whites (HR = 0.873, 95%CI 0.853-0.893, P < .001, and HR = 0.958, 95%CI 0.937-0.979, P < .001, respectively). Blacks had the worst CRC-specific survival outcomes when compared to Whites (HR = 1.215, 95%CI 1.192-1.238, P < .001). Racial disparity persisted when looking at two different time periods (1994-2003 and 2004-2014). CONCLUSIONS: Asians/Pacific Islanders have improved outcomes from CRC compared to other races. Multifactorial, including genetic, environmental, and socioeconomic factors appear to influence outcomes and need to be addressed separately in order to reduce racial disparities among patients with CRC.
Entities:
Keywords:
Cancer outcomes; Colorectal cancer; Racial disparities; SEER
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Ann Intern Med Date: 2007-10-16 Impact factor: 25.391
Authors: Hassan Ashktorab; Duane T Smoot; Haleh Farzanmehr; Marie Fidelia-Lambert; Bahram Momen; Linda Hylind; Christine Iacosozio-Dononue; John M Carethers; Ajay Goel; C Richard Boland; Francis M Giardiello Journal: Int J Cancer Date: 2005-10-10 Impact factor: 7.396
Authors: Wendy Lee; Rebecca Nelson; Brian Mailey; Marjun Philip Duldulao; Julio Garcia-Aguilar; Joseph Kim Journal: J Gastrointest Surg Date: 2012-01-19 Impact factor: 3.452
Authors: Ryan J Ellis; Cary Jo R Schlick; Joe Feinglass; Mary F Mulcahy; Al B Benson; Sheetal M Kircher; Tony D Yang; David D Odell; Karl Bilimoria; Ryan P Merkow Journal: BMJ Qual Saf Date: 2019-07-31 Impact factor: 7.035
Authors: Kristen S Purrington; Ann G Schwartz; Julie J Ruterbusch; Mark A Manning; Mrudula Nair; Angela S Wenzlaff; Stephanie S Pandolfi; Michael S Simon; Jennifer Beebe-Dimmer Journal: Cancer Date: 2020-08-04 Impact factor: 6.860
Authors: Mohamed M Gad; Mihnea-Alexandru Găman; Anas M Saad; Muneer J Al-Husseini; Omar A Shehata; Mohannad Abou Saleh; Alfred D Nelson; Carlos Roberto Simons-Linares Journal: Ann Gastroenterol Date: 2020-02-12
Authors: Julia D Labadie; Sevtap Savas; Tabitha A Harrison; Barb Banbury; Yuhan Huang; Daniel D Buchanan; Peter T Campbell; Steven J Gallinger; Graham G Giles; Marc J Gunter; Michael Hoffmeister; Li Hsu; Mark A Jenkins; Yi Lin; Shuji Ogino; Amanda I Phipps; Martha L Slattery; Robert S Steinfelder; Wei Sun; Bethany Van Guelpen; Xinwei Hua; Jane C Figuieredo; Rish K Pai; Rami Nassir; Lihong Qi; Andrew T Chan; Ulrike Peters; Polly A Newcomb Journal: Sci Rep Date: 2022-01-07 Impact factor: 4.996